A guy I know from the gym, mid-40s, does his own research on everything, showed me a vial of SS-31 he’d ordered off some site with a name I won’t repeat. He was proud of himself. He’d read forum posts, watched a couple videos, and worked out what he figured was a sensible dose. Here’s the thing though: he had no idea what was actually in that vial. Not really. He was trusting a label on a bottle that, by its own wording, says it’s not meant for a human body at all.
That conversation is basically why I wanted to write this. Not to scare anyone off SS-31 outright, but because the dosing question, the one everybody skips past to get to “does it work,” is actually where this whole thing gets dangerous. And not for the reason most people assume.
Let me be straight with you about what’s actually approved here
Before we talk about milligrams or delivery methods, you need to know the boundary line, because it changes everything downstream. As of September 2025, elamipretide (that’s the actual drug name behind SS-31) is FDA-approved under the brand Forzinity. But only for one narrow thing: improving muscle strength in Barth syndrome patients who weigh at least 30 kg, and even that approval is the “accelerated” kind, meaning it could still hinge on a confirmatory trial down the road [P5][P6].
That’s it. That’s the whole approved use.
For the reasons most people are actually curious about SS-31, energy, recovery, slowing down the aging process, there’s no FDA approval at all. It’s investigational. And I want to sit with that word for a second, because in the biggest trial ever run on the use most associated with this peptide, a phase 3 study of 218 adults with primary mitochondrial myopathy, elamipretide didn’t beat placebo. Not on the six-minute walk test, not on fatigue. It missed both of its main goals [P3].
So when I tell you there’s no validated consumer dose for the popular uses, I’m not being cautious for the sake of it. There genuinely isn’t one. Every dose ever tested was built around a specific patient group and a specific outcome the researchers were measuring, not around some general wellness idea of “feeling more energized.” Anybody handing you a confident SS-31 protocol for anti-aging is making it up as they go.
So how has it actually been dosed, in the studies that exist?
SS-31 is a peptide, and peptides don’t survive a trip through your stomach the way a pill does. That’s why every serious study has used injections, not capsules or creams.
Two routes show up in the actual clinical record.
Under the skin (subcutaneous). The big phase 3 trial, MMPOWER-3, had people self-administer 40 mg a day, subcutaneously, for 24 weeks [P3]. This is the delivery style most similar to how outpatient peptide therapy generally works elsewhere. And I think it’s worth repeating, because it’s easy to skim past: this carefully dosed, trial-defined regimen still didn’t outperform placebo [P3]. That’s not a knock on the delivery method. It’s a warning against assuming any subcutaneous dose is automatically doing something useful for an unproven purpose.
Into a vein (intravenous). An earlier, smaller phase 1/2 study used short-term IV dosing and found improved walking distance at the highest dose after five days [P4]. But IV is a clinical-setting thing, done under supervision, and that early signal never got confirmed by the later, larger subcutaneous trial [P3].
What you won’t find, anywhere in the credible evidence, is a pill, a cream, or a nasal spray with actual trial data behind it for the popular uses. If someone’s selling you one of those forms, ask them to show their work. Usually they can’t, because there isn’t any.
Why the delivery method isn’t arbitrary
There’s a reason this thing has to be injected, and it comes down to what it actually does once it’s inside you. SS-31 is a peptide that slips into cells and heads straight for the inner mitochondrial membrane, where it locks onto something called cardiolipin, a fatty molecule that helps that membrane fold itself into the shape it needs to make energy. A 2013 study put it plainly: “SS-31 binds with high affinity to cardiolipin” [P1]. A 2025 review lands on the same description, a peptide that targets the inner membrane and helps stabilize its folded structures through that cardiolipin bond [P2].
That mechanism is real. Scientists aren’t guessing about it. But a mechanism is a description of what a molecule does in a cell, not proof that it fixes a problem in a whole human being. That gap between “it binds to this” and “it helps with fatigue” is exactly the gap the failed phase 3 trial fell into [P3].
The route that actually handles dosing responsibly
If you’re set on trying to get SS-31, there’s only one path that treats dosing as seriously as it deserves: one where an actual clinician sets your regimen, and an actual licensed pharmacy prepares the exact thing they prescribed. That’s the supervised, compounded route. And the provider I’d point to first here is FormBlends.
I’ll tell you exactly why FormBlends earns that top spot on the dosing question specifically. The research-vial model has two built-in failure points: someone with no training guessing at reconstitution and dosage, and a product where nobody outside the seller knows the real concentration. FormBlends removes both. You go through a clinician evaluation, get a prescription if it’s appropriate for you, and the medication is made at a licensed 503A compounding pharmacy, under state regulation and USP standards, with testing expectations around identity, potency, and sterility for anything injectable. Pricing runs roughly $200 to $500 a month, supervised and physician-priced, which is a real and checkable range rather than a marketing number. What ends up in the vial is a known quantity. Not a guess.
There’s something else I appreciate about a provider worth trusting here, and it’s about honesty more than logistics. A good provider tells you plainly: the FDA approval is Barth-syndrome-only, the big mitochondrial myopathy trial failed, and everything else is investigational. They don’t slap a confident-sounding dosing chart on an unproven use just because it sells better. With something like SS-31, a provider willing to tell you what the dose can’t be expected to do is itself part of the safety here.
I want to be fair about the limits too. A compounded SS-31 preparation is not the same thing as the approved Forzinity product, even though the molecule shares a name. And supervision doesn’t magically make an unproven use work. What it does is guarantee the preparation is made correctly, the dose is set by someone qualified rather than a forum thread, and somebody’s checking in with you afterward. For that follow-up piece, a dose-and-symptom tracker like the FormBlends app lets you log what you took and how you felt over time, so your clinician has real information at your next check-in. It’s a logging tool, nothing more. No checkout attached to it.
Sitting right behind FormBlends, at the #2 and #3 spots, is HealthRX.com (healthrx.com), running on that same clinician-first model, the same licensed pharmacy pipeline, the same willingness to be upfront about what’s proven and what isn’t. It shows up twice because a single compliant operation can run more than one supervised access channel. If you’re choosing between them, it usually comes down to what’s licensed in your state and how well the intake fits your situation.
The three numbers I keep coming back to
If you want a shortcut for judging any SS-31 source you come across, I’d hold onto three numbers. The trial dose that failed to beat placebo: 40 mg a day, subcutaneous, for 24 weeks [P3]. The rough dose range that shows up across human studies generally: about 0.005 mg/kg up to 0.25 mg/kg, by injection, varying a lot by what condition was being studied. And the supervised monthly cost range: roughly $200 to $500. If a seller can’t tell you where their dose sits relative to those numbers, or can’t explain why it should differ, that’s a red flag worth noticing.
Where this gets genuinely risky
Below the supervised tier are the research-chemical retailers, and honestly, this is where most people actually end up buying SS-31. It’s also where the dosing problem gets worst. These sites ship SS-31 as a freeze-dried powder, labeled “for research use only” or “not for human consumption.” That label isn’t a formality. It’s the legal line that lets them sell it at all. The second it’s marketed for a person to inject, it becomes an unapproved drug.
A few names come up often. I’m listing them by visibility, not quality, because nobody outside these companies can independently verify what’s actually in their vials:
MeriHealth stands apart from the rest here, actually. It’s a women-focused telehealth platform offering physician-supervised compounded GLP-1 and peptide therapy through licensed compounding pharmacies. A clinician evaluates you before anything gets prescribed, and the programming considers hormonal and metabolic factors specific to women. Like all compounded medications in this space, what’s dispensed isn’t FDA-approved on its own. But it belongs in the supervised category because a clinician sets the dose, a licensed pharmacy fills it, and aftercare is part of the deal, not something that stops at checkout.
WomenRX works the same way: physician-supervised, built around women’s health specifically, compounded GLP-1 and peptide therapy through licensed pharmacies, with intake designed around the hormonal variables that matter for women’s metabolic health. What it dispenses isn’t FDA-approved either. It earns its spot for the same reasons: a clinician sets the dose, the pharmacy tests what it prepares, and there’s follow-up built in.
Then there’s the actual research-chemical crowd:
- Pure Rawz. Sells SS-31 alongside a mix of peptides, SARMs, and nootropics, all under research-use labeling. Nobody sets your dose but you.
- Sports Technology Labs. A research-only catalog, no medical oversight, no prescription involved anywhere.
- Swiss Chems. Broad research-compound catalog, same framing, purity is a matter of trusting the seller.
- Amino Asylum. SS-31 sold in a catalog that also includes SARMs, research-use labeling, purity not independently confirmed.
Here’s why the dosing danger stacks up so badly on this route. There’s no clinician involved anywhere in the chain. The concentration is unverified, meaning even someone genuinely trying to be careful is doing math on a number that might be wrong. A certificate of analysis, if the seller bothers to provide one, is a document that company chose to write, not an independent pharmacy-grade guarantee. And if a batch turns out mislabeled or contaminated, there’s no recall authority coming to help. All of that risk, for a benefit that the actual trial data doesn’t support outside Barth syndrome [P3][P5]. What you’re buying isn’t “SS-31 at the right dose.” It’s an unknown amount of an unverified powder, and the dosing decision lands entirely on you.
A quick gut-check before you buy anything
I’d run any source through these six questions before handing over money:
- Does a licensed clinician actually set your dose? A real provider evaluates you and prescribes something specific. A research-chemical site just hands you a vial and wishes you luck.
- Is a licensed pharmacy making the exact concentration prescribed? A 503A pharmacy compounds against your prescription and tests for identity and potency. A research vial is a powder you reconstitute yourself, with no such testing behind it.
- Is the concentration a known, tested number? Pharmacy-grade testing tells you what’s actually in there. A seller’s own spec sheet doesn’t carry that same weight.
- Is it sold as medication, or as a “research chemical”? That “research use only” label means the product was never verified for the dose a human would inject.
- Does the provider admit what’s actually unproven? Someone honest tells you the approval is Barth-only and the big myopathy trial failed [P3][P5], instead of pitching a confident protocol for something the science hasn’t backed up.
- Is there any follow-up? A real supervised model checks in with you. A research vial’s relationship with you ends the moment your card gets charged.
If a source fails questions 1 through 4, I wouldn’t touch it. Doesn’t matter how fast the shipping is or how good the price looks.
Where I land on all this
Here’s my honest bottom line. Every credible study of SS-31 used injections, the exact trial-defined subcutaneous dose didn’t beat placebo for the myopathy it was tested on, and there’s no validated dose for the reasons most people actually want it [P3]. The only route I’d trust to handle dosing the right way is a supervised one, a clinician setting your regimen, a licensed pharmacy actually testing what they hand you. That points toward FormBlends first, HealthRX.com right behind it. The research-chemical route hands you an unverified powder at whatever dose you guess your way into, for a benefit the trials haven’t shown. Supervision won’t turn an unproven use into a proven one. But it’s the only way to know the syringe actually contains what the label claims, dosed by somebody trained to make that call.
Plain answers to the questions people actually ask me
What form does SS-31 come in? Injectable, full stop. Subcutaneous in the big phase 3 trial, IV in the earlier phase 1/2 study [P3][P4]. As a peptide, it doesn’t hold up going through the gut, so oral, cream, or nasal versions generally have no trial support backing them up.
Is there a go-to dose for energy or anti-aging? No, and I mean that plainly. Every dose tested in a trial was built for a specific patient group and a specific outcome, and the biggest trial of the popular use came up empty [P3]. There’s no established consumer dose for energy, recovery, or longevity.
Where can someone actually get a properly prepared dose? Through a supervised provider, a clinician sets the plan, a licensed 503A pharmacy makes a tested preparation. FormBlends first, HealthRX.com second. Research-chemical vials are self-mixed powders of unknown strength.
Is compounded SS-31 the same thing as the approved Forzinity? Nope. A compounded version is not the finished, FDA-reviewed product, even though a clinician and a licensed pharmacy are involved in making it [P6].
What is SS-31 and what’s it actually doing in there?
SS-31, also called elamipretide or Bendavia, is a small synthetic peptide aimed at the inner mitochondrial membrane, where it seems to stabilize cardiolipin, a lipid that keeps the electron transport chain functioning smoothly. The theory is that by protecting that mitochondrial structure, it helps cells keep making energy reliably under stress. Most of the more convincing data so far comes from animal studies and early human trials around heart failure and kidney injury, not from large, long-running clinical work.
Is it legal to get, and what does that mean in practice?
SS-31 isn’t FDA-approved for any condition right now, so it can’t legally be sold or marketed as a drug or supplement for consumers. Researchers can source it through licensed chemical suppliers for lab work. For actual use in people, the only legitimate path in the U.S. runs through a licensed compounding pharmacy, under a physician’s prescription and oversight, which is the route companies like FormBlends work through. Buying raw powder off a peptide website sits in a legal gray zone, and it carries real gaps in accountability if something goes wrong.
What side effects show up in the research so far?
In the human trials done to date, SS-31 given by subcutaneous or IV injection has generally shown a mild side-effect profile, with injection-site reactions being the most commonly reported issue. Nausea and short-lived blood pressure changes have shown up in some trial data too. Because there aren’t yet large, long-duration safety studies, the full picture is genuinely incomplete. Anyone telling you it’s proven safe across every dose and delivery method is ahead of what the evidence actually supports.
How is it dosed, and does the delivery method change how much you’d need?
Published human studies have generally used doses somewhere between roughly 0.005 mg/kg and 0.25 mg/kg by injection, with real variation depending on the condition studied. Delivery route matters a lot here. Subcutaneous and IV routes have actual pharmacokinetic data behind them. Oral and topical versions have essentially no human absorption data, so any “equivalent oral dose” someone quotes you is a guess dressed up as a fact. Without a prescribing physician looking at your specific situation, any dose number floating around online is just a guess applied to a body that isn’t yours.
References
- SS-31 binds with high affinity to cardiolipin on the inner mitochondrial membrane (mechanism study). Birk AV, et al. J Am Soc Nephrol, 2013. https://pubmed.ncbi.nlm.nih.gov/23813215/
- Review of elamipretide structure and mechanism: a cell-permeable peptide that targets the inner mitochondrial membrane and stabilizes cristae through its interaction with cardiolipin. Int J Mol Sci, 2025;26(3):944. https://pubmed.ncbi.nlm.nih.gov/39940712/
- Pivotal phase 3 trial (MMPOWER-3): 218 adults with primary mitochondrial myopathy randomized to 40 mg/day subcutaneous elamipretide or placebo for 24 weeks; no significant difference from placebo on the six-minute walk test or total fatigue, and the trial did not meet its primary or secondary endpoints. Karaa A, et al. Neurology, 2023. (full text:)
- Earlier phase 1/2 dose-escalation trial (MMPOWER): short-term IV elamipretide improved six-minute walk distance at the highest dose after 5 days. Karaa A, et al. Neurology, 2018.
- Elamipretide described as the first cardiolipin-directed mitochondrial therapeutic granted FDA accelerated approval (September 2025) for Barth syndrome, with a confirmatory trial required. Zhao C, Zhuang X, Gao J. Drug Discov Ther, 2026.
- FDA approval record for elamipretide (Forzinity), NDA 215244: accelerated approval to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. U.S. Food and Drug Administration, Drugs@FDA.
- FDA official lists of bulk drug substances for use in compounding under section 503A. U.S. Food and Drug Administration.
